logo
Father fights off mountain lion to save 4-year-old in Olympic National Park

Father fights off mountain lion to save 4-year-old in Olympic National Park

Yahoo4 days ago
A father's split-second decision saved his child's life.
A peaceful family outing at Washington's Olympic National Park turned into a nightmare when a mountain lion attacked a 4-year-old child, leading to a dramatic rescue by the child's father that witnesses are calling heroic.
The attack occurred Sunday afternoon around 3:15 p.m. on Hurricane Ridge Trail, one of the park's most popular hiking destinations, known for its expansive mountain views. The family was walking the well-traveled path when a collared mountain lion suddenly bit the young child.
According to the National Park Service, the child's father immediately sprang into action, physically intervening to get his child away from the dangerous predator. Witnesses at the scene praised the father's quick thinking and brave response, crediting his actions with potentially saving the child's life.
"I don't think that kid would survive if it wasn't for his dad jumping in," said Steve Murrow, who was hiking nearby with his family when the attack occurred. "He's a hero. It just boils down to safety in numbers, and it is rare that something like this would happen."
Murrow and his father-in-law heard the child's screams and rushed to the area, where they found the mother holding her injured child while other hikers provided comfort and assistance to the shaken family.
Park rangers and paramedics quickly responded to the emergency call, airlifting the child to Harborview Medical Center in Seattle for treatment. Hospital officials later confirmed the child was in satisfactory condition and has since been released.
The mountain lion, which was fitted with a research tracking collar, remained in the area after the attack. Rangers launched an immediate search effort, joined by a specialized canine team around 5 p.m. The animal was located shortly after and subsequently killed by park officials, who stated there was no ongoing threat to public safety.
What to do if you see a mountain lion
This incident serves as a stark reminder of the importance of wilderness safety awareness. The U.S. Fish and Wildlife Service advises anyone encountering a mountain lion to make themselves appear larger and more aggressive by opening jackets, raising arms, and throwing stones or branches while maintaining eye contact. Crucially, experts warn never to run from a mountain lion, as this can trigger their chase instinct.
Mountain lion attacks on humans are extremely rare, making this incident particularly unusual for the popular tourist destination. The National Park Service is asking any witnesses to the attack to contact them at 888-653-0009 or email nps_isb@nps.gov as they continue investigating the circumstances surrounding the encounter.
The family's identity is being protected for privacy reasons, but their experience highlights two things: the unpredictable nature of wildlife encounters, and the powerful instinct of a parent to protect their child at any cost.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Yahoo

timean hour ago

  • Yahoo

Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty

Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death

Yahoo

timean hour ago

  • Yahoo

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death

Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death originally appeared on Parade. Wrestling icon Hulk Hogan has died at the age of 71, following a reported cardiac arrest. The shocking news comes after Hogan opened up about his declining health and the toll his legendary wrestling career had taken on his body. Hulk Hogan Had 25 Surgeries in 10 Years In a September 2024 appearance on Logan Paul's 'IMPAULSIVE' podcast, Hogan revealed that he had undergone a staggering 25 surgeries over the past decade. 'I've had like 25 surgeries in the last ten years. Ten of them were back surgeries,' Hogan told Paul. 'Nobody told me this gimmick stuff was fake. I've had 10 back surgeries, both knees and both hips replaced, shoulders — everything.' The WWE Hall of Famer also reflected on the physically punishing early days of professional wrestling. He recalled how Andre the Giant once warned him about the dangerous condition of older wrestling rings. 'The equipment back in the day when I started wrestling in '77 was a little different than the rings and stuff you guys are working in now,' Hogan said. 'Andre used to tell me, 'Boss, don't fall down. You won't get back up.' It was like a 22-foot boxing ring that had lumps in it, boards sticking up—it was horrible.' Hulk Hogan's Health Issues Before His Death In the months leading up to his death, Hogan's public appearances sparked concern among fans. After appearing on Fox & Friends to promote his new wrestling league, many noted the WWE icon looked 'unwell.' Soon after, Hogan was reportedly hospitalized for neck and back issues, undergoing a minor cervical fusion surgery. Rumors quickly spread that he was on his 'deathbed,' but his representatives shut down those claims. 'He just needs from time to time a medical check-up,' a spokesperson reportedly told The Independent, adding there were 'no reasons to panic.' Hulk Hogan's Cause of Death: Cardiac Arrest Reported As of now, Hogan's cause of death is being reported as cardiac arrest, though official confirmation and more details are expected in the coming days. Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death first appeared on Parade on Jul 24, 2025 This story was originally reported by Parade on Jul 24, 2025, where it first appeared.

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Yahoo

timean hour ago

  • Yahoo

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store